Hematology for the Oncologist

Hematologic Malignancies
Multiple Myeloma
Myelodysplastic Syndromes

Selected Abstracts on Novel Therapies for Hematologic Malignancies

Syed A. Abutalib, MD  / August 10, 2017  / Umbraco.Web.PublishedCache.XmlPublishedCache.XmlPublishedContent

THE 22ND CONGRESS of the European Hematology Association (EHA) was held in June in Madrid, drawing hematologists and allied professionals from every subspecialty of hematology from around the world. Among the extensive educational and scientific program, the EHA Congress provides a forum for pr...

Supportive Care

Update on Novel Anticoagulants: Dabigatran Etexilate

Rajiv K. Pruthi, MBBS  / April 15, 2012

Efficacy and safety of traditional anticoagulants (eg, vitamin K antagonists) are well recognized, given their long-standing use in clinical practice. However, the novel anticoagulants have several potential advantages over the vitamin K antagonists. Even so, in light of their recent introduction in...

Hematologic Malignancies

How I Work up the Patient with Thrombocytosis

Ayalew Tefferi, MD  / March 15, 2012

Thrombocytosis is defined as a platelet count greater than 400 × 109/L. In routine clinical practice, thrombocytosis is much more likely to be reactive (> 80% of cases) than primary. Reactive thrombocytosis is usually associated with infections, inflammation, trauma, hemolysis, metastatic cancer,...

Hematologic Malignancies

JAK2 and MPL Mutation Screening: What Are the Indications and How to Interpret the Results

Ayalew Tefferi, MD  / February 15, 2012

The World Health Organization system organizes myeloid malignancies into five major categories, which are subsequently further subclassified using a combination of bone marrow morphology and cytogenetic/molecular information (Table 1).1 JAK2 and MPL mutations are not disease-specific and occur acros...